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Abstract
The Caenorhabditis elegans dosage compensation complex (DCC) equalizes X-chromosome gene dosage between XO males
and XX hermaphrodites by two-fold repression of X-linked gene expression in hermaphrodites. The DCC localizes to the X
chromosomes in hermaphrodites but not in males, and some subunits form a complex homologous to condensin. The
mechanism by which the DCC downregulates gene expression remains unclear. Here we show that the DCC controls the
methylation state of lysine 20 of histone H4, leading to higher H4K20me1 and lower H4K20me3 levels on the X
chromosomes of XX hermaphrodites relative to autosomes. We identify the PR-SET7 ortholog SET-1 and the Suv4-20
ortholog SET-4 as the major histone methyltransferases for monomethylation and di/trimethylation of H4K20, respectively,
and provide evidence that X-chromosome enrichment of H4K20me1 involves inhibition of SET-4 activity on the X. RNAi
knockdown of set-1 results in synthetic lethality with dosage compensation mutants and upregulation of X-linked gene
expression, supporting a model whereby H4K20me1 functions with the condensin-like C. elegans DCC to repress
transcription of X-linked genes. H4K20me1 is important for mitotic chromosome condensation in mammals, suggesting that
increased H4K20me1 on the X may restrict access of the transcription machinery to X-linked genes via chromatin
compaction.
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Introduction
In many animals, males and females have a different number of
X chromosomes. Dosage compensation is a chromosome-wide
process of gene regulation that equalizes gene expression between
the sexes despite the difference in X-linked gene dosage, and is
achieved by a variety of mechanisms [1,2]. In humans, one X
chromosome is inactivated in females. In Drosophila, expression
from the single X chromosome in males is upregulated two-fold to
match expression from the two X chromosomes in females. In C.
elegans, the two X chromosomes in hermaphrodites are downreg-
ulated two-fold to match expression from the single X chromo-
some in males. In each of these cases, regulation of gene expression
involves the targeting of specialized protein complexes specifically
to the X chromosome. Studies of different dosage compensation
mechanisms have uncovered chromatin-mediated mechanisms of
gene regulation.
In C. elegans, dosage compensation is achieved by the dosage
compensation complex (DCC) (reviewed in [3]). The core of the
DCC consists of a five-subunit condensin complex named
condensin IDC. Condensin complexes mediate chromosome
condensation and resolution in mitosis and meiosis, and partici-
pate in crossover control during meiosis [4]. Four subunits (MIX-
1, DPY-26, DPY-28, and CAPG-1) are shared with canonical
condensin I, while DPY-27 is specific to condensin IDC [5]. The
central role of a condensin-like complex in dosage compensation
suggests that the mechanism of dosage compensation involves
regulation of chromatin structure. Five other components of the
DCC (SDC-1, SDC-2, SDC-3, DPY-21 and DPY-30) physically
interact with different subunits of condensin IDC, and all examined
components of the DCC are enriched on hermaphrodite X
chromosomes relative to autosomes [3].
The DCC is targeted to the X chromosome through specific
sequence elements, called rex (recruitment elements on X) sites
(reviewed in [3]). After recruitment, the DCC spreads to dox
(dependent on X) sites, which consist mostly of active promoters.
The zinc finger protein SDC-2 is the primary X-chromosome
recruitment factor for the DCC. The DCC also binds to some
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autosomal sites at lower levels, but the functional significance of
autosomal binding is not yet known [6,7]. SDC-3 requires SDC-2
for X-chromosome binding, and all of the other DCC components
require SDC-2 and SDC-3 for recruitment. Loss of DCC proteins
impairs dosage compensation, resulting in upregulation of X-
linked genes and death of XX animals. DPY-21 and SDC-1 null
mutants have milder dosage compensation defects and are viable,
with apparently normal DCC protein localization on X
[8,9,10,11,12].
A current model is that SDC proteins recruit condensin IDC to
the X chromosome, leading to changes in chromatin structure that
result in reduction of gene expression. In XX animals, not all
genes on X are dosage compensated, and DCC association with
genes correlates with gene expression level but not with the degree
of repression [7]. The mechanism of repression is not understood,
but DCC mutants have increased levels of RNA polymerase II on
X-linked genes, indicating regulation at the level of transcription
[13].
Here we show that the DCC is required for enrichment of the
histone modification H4K20me1 on the X chromosomes of
hermaphrodites and that the responsible histone methyltransferase
SET-1 is important for downregulation of dosage-compensated
genes. Our study implicates the histone modification H4K20me1
in the process of dosage compensation.
Results
The localization of dosage compensation proteins to the X
chromosome become apparent at around the 30-cell stage of
embryogenesis [3,14]. Our previous experiments mapping the
genome-wide patterns of H4K20me1 suggested that this histone
modification might function in dosage compensation: H4K20me1
is weakly enriched on the X chromosome in early embryo
populations that span initiation of dosage compensation (1–300-
cell stages with 76%,100-cell) and strong enrichment at the third
larval (L3) stage, when dosage compensation is fully active
(Figure 1A) [15]. We performed additional ChIP experiments to
better define the timing of H4K20me1 enrichment on X. We
found that late embryos (99% 100-cell to 3-fold stage), which have
activated dosage compensation, display high H4K20me1 on the
X, similar to the pattern in L3 larvae (Figure 1A). Moreover,
enrichment on the X chromosome is maintained in adult
hermaphrodites (Figure 1A). Therefore, H4K20me1 is enriched
on the X chromosome at developmental stages when dosage
compensation is active.
H4K20me1 is enriched in both coding and non-coding
regions along the X chromosome in dosage-
compensating XX hermaphrodites
In C. elegans, dosage compensation downregulates genes on the
X chromosome. We therefore examined the pattern of
H4K20me1 with respect to gene features. As seen previously in
early embryos and L3 larvae [15], H4K20me1 is enriched across
active gene regions at all developmental stages examined, with
high enrichment on X-linked genes and lower enrichment on
autosomal genes (Figure 1C). H4K20me1 levels are positively
correlated with transcript levels for both X-linked and autosomal
genes (rs = 0.66 and rs = 0.56, respectively). Notably, inactive X-
linked genes have higher levels of H4K20me1 than active
autosomal genes (Figure 1C). On autosomes H4K20me1 is
primarily confined to transcribed regions, while on the X,
H4K20me1 is elevated across the chromosome, including regions
that are more than 5 kb from any annotated gene feature
(Figure 1D). This widespread distribution of H4K20me1 on the X
chromosome suggests a role in chromosome-wide regulation of
gene expression.
H4K20me1 is enriched on the X after the onset of dosage
compensation
Our ChIP experiments from early and late stage embryos, L3s,
and young adults showed that the timing of H4K20me1
enrichment on the X chromosome is consistent with a role in
dosage compensation. To determine more precisely when
H4K20me1 becomes enriched on the X chromosome, we
performed immunofluorescence experiments using two different
antibodies specific for H4K20me1. In embryos prior to the 30-cell
stage, neither DPY-27 nor H4K20me1 was concentrated in any
subnuclear region (Figure 2A). However, we observed that nuclear
staining of H4K20me1 increased dramatically during mitosis
(Figure 2A and Figure S1). This is consistent with reports showing
that in other organisms, H4K20me1 is present at high levels in
mitosis and has a role in chromosome condensation [16]. At
around the 30-cell stage, DPY-27 became localized to subregions
of each nucleus that have been shown to be the X chromosomes
[14] (Figure 2B, 2F). At this time, H4K20me1 was still distributed
uniformly in the nucleus (Figure 2B, 2F). In embryos beginning the
differentiation stage, H4K20me1 staining began to concentrate on
the X chromosomes, as evidenced by colocalization with DPY-27,
and this pattern became widespread in somatic cells throughout
hermaphrodite development (Figure 2D, 2E, 2G; Figure S2A).
Therefore, localization of the DCC to the X chromosome
precedes enrichment of H4K20me1.
H4K20me1 is reduced on the X in the germ line during
meiotic silencing
In the germ line, the DCC does not localize to the X
chromosome [10]. The X chromosome is largely silent, and the
silent state is mediated by a mechanism independent from somatic
dosage compensation [10,17,18,19]. We observed a distinct and
dynamic pattern of H4K20me1 staining in the adult germ line.
H4K20me1 levels were highest in the distal mitotic region, and
Author Summary
In many animals, males have one X chromosome and
females have two. However, the same amount of gene
expression from X chromosomes is needed in the two
sexes. The process of dosage compensation (DC) globally
regulates X-chromosome gene expression to make it equal
between the sexes, and it occurs in different ways in
different animals. In mammals, one X chromosome in
females is randomly inactivated, leaving one active X
chromosome. In contrast, in the nematode worm C.
elegans, the two X chromosomes in hermaphrodites are
repressed two-fold to match gene expression to the single
X chromosome in males. Previous work in C. elegans
identified proteins required for DC that bind to the X
chromosome, but their mode of action is not known. Here
we show that DC proteins lead to higher levels of histone
H4 lysine 20 monomethylation (H4K20me1) on hermaph-
rodite X chromosomes and that H4K20me1 functions in
repressing X-chromosome gene expression. This shows
that histone modification is an important aspect of the
mechanism of dosage compensation. Together with
previous work linking H4K20me1 to chromatin structure
regulation, our results suggest that dosage compensation
might lower gene expression on hermaphrodite X chro-
mosomes by compacting them.
H4K20me1 and Dosage Compensation
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decreased as nuclei entered meiosis (Figure S3A). Early meiotic
nuclei entering the transition zone showed similar H4K20me1
levels on X and autosomes (Figure S3B). As nuclei progressed
through the transition zone into early pachytene, H4K20me1
levels were much lower on the X chromosome than on autosomes
(Figure S3B). The X chromosome is silent during early and mid-
Figure 1. H4K20me1 becomes enriched on the X chromosome in wild type but not in a mutant defective in dosage compensation.
(A) Genome browser tracks of indicated ChIP signals across representative regions of chromosome I and chromosome X in wild-type early embryos
(EE), late embryos (LE), L3 larvae (L3), and fem-2 female young adults (YA). For each track, the average of two independent biological replicates is
shown as z-scores (standardized log2 ratios of ChIP/Input signals). High H4K20me1 enrichment on X begins in late embryos. A track of DPY-27 (a DCC
component) is shown for reference. (B) Enrichment of H4K20me1 on the X is lost in dpy-21 mutants. (C) Plots of H4K20me1 and H4K20me3 signal
across the TSS (transcript start site) and TES (transcript end site) of genes on X (red) and autosomes (blue). Genes in the top 20% of expression (dark
shades) and bottom 20% (light shades) are plotted separately. (D) Plots of H4K20me1 and H4K20me3 signal centered at intergenic regions at least
5 kb from any annotated feature. (E) Box plots of overall H4K20me1 and H4K20me3 signals on each chromosome. Each box shows the median and
extends from the 25th to the 75th percentile of the z-scores in the set; whiskers extending from the box indicate the 2.5th and 97.5th percentiles.
doi:10.1371/journal.pgen.1002933.g001
H4K20me1 and Dosage Compensation
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pachytene [18]. Later in meiotic prophase, H4K20me1 levels
increased on the X, coincident with activation of X-linked gene
expression (Figure S3B; [18]). In contrast to the enrichment of
H4K20me1 on the X chromosome in somatic nuclei, levels of
H4K20me1 in late meiotic prophase were similar on the X
chromosome and autosomes (Figure S3B). To summarize,
H4K20me1 shows a dynamic localization pattern on germline
chromatin, with two characteristics of localization shared with
somatic chromatin. First, enrichment of H4K20me1 is observed
on mitotic chromosomes. Second, in meiotic nuclei, H4K20me1 is
associated with chromatin that has active gene expression.
H4K20me1 enrichment on the X depends on DCC
function
To test whether H4K20me1 enrichment on the X chromosome
depends on the DCC, we carried out H4K20me1 ChIP-chip
experiments using extracts from dpy-21 mutant L3 larvae, which
Figure 2. H4K20me1 becomes concentrated on the X chromosome after the DCC.Wild-type embryos at (A) 20-cell, (B) 40-cell, (C) bean, (D)
comma, and (E) three-fold stages stained for DNA (DAPI, blue, left column), DPY-27 (red, second column), and H4K20me1 (green, third column).
Boxed regions in B and E are enlarged in F and G, respectively. In very early embryos (A) DPY-27 exhibits weak and diffuse nuclear staining while
H4K20me1 is diffuse in interphase nuclei and associated with condensed chromatin during mitosis. By the,40-cell stage (B, F) DPY-27 is enriched on
the X chromosome, while H4K20me1 continues to show a uniform nuclear distribution. Comma-stage embryos (D) contain some nuclei with
H4K20me1 enrichment on the X. This enrichment becomes more apparent as embryogenesis progresses, and by the 3-fold stage (E, G) H4K20me1 is
concentrated in bright foci that co-localize with DPY-27 on the X. Scale bars represent 10 um (A–E) and 2 um (F, G). Monoclonal antibody15F11 was
used to detect H4K20me1.
doi:10.1371/journal.pgen.1002933.g002
H4K20me1 and Dosage Compensation
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are deficient in dosage compensation [12]. Strikingly, H4K20me1
enrichment on the X relative to autosomes was abolished in dpy-21
mutants (Figure 1B–1F), indicating that the DCC facilitates
enrichment of H4K20me1 on the X. To further investigate this
link, we asked whether the DCC could increase H4K20me1 levels
at ectopic sites. Previous studies showed that DCC proteins bind
recruiting elements on the X and then spread to neighboring
regions that lack recruiting sites [6,20]. Spreading is observed in
chromosomal fusions between the X chromosome (which contains
recruiting sites) and an autosome (which lacks recruiting sites;
Figure 3). Using this assay, we observed spreading of H4K20me1
into the autosomal region flanking the site of the fusion, similar to
that seen for the DCC component DPY-27 (Figure 3). This is
consistent with a direct role for the DCC in generating enrichment
of H4K20me1 on the X.
To better define the timing and requirement for dosage
compensation in H4K20me1 enrichment on the X, we performed
immunofluorescence experiments on dosage compensation mutant
embryos. H4K20me1 was not enriched on the X chromosome in
any dosage compensation mutant tested (dpy-21, dpy-26, dpy-28,
and dpy-30; Figure 4 and Figure S4). Instead, H4K20me1 was
evenly distributed on all chromosomes. We next analyzed XO
males, which do not undergo dosage compensation and found no
H4K20me1 enrichment on the single X of XO embryos or XO
adult somatic nuclei (Figure 4B, Figures S2B and S4B). We also
observed no H4K20me1 enrichment to X in adult gut nuclei of
DCC mutants, similar to [21] (Figure S2). These results indicate
that the DCC is required for the X-chromosome enrichment of
H4K20me1.
SET-1 and SET-4 enzymes generate H4K20me1 and
H4K20me2/3, respectively
To determine whether H4K20me1 functions in dosage com-
pensation, we sought to identify the enzymes responsible for
methylation of H4K20. In other organisms, PR-Set7/SETD8
catalyzes monomethylation of H4K20 and Suv4-20 catalyzes di-
and trimethylation of H4K20 [22,23,24]. The C. elegans orthologs
of these proteins are SET-1 (PR-Set7/SETD8) and SET-4 (Suv4-
20). Deletion mutants for both genes are available: set-1(tm1821)
homozygotes develop into sterile adults (S. Mitani, pers. comm.),
whereas set-4(n4600) homozygotes are viable and fertile [25].
Among embryos from fertile set-1/balancer mothers, heterozy-
gous set-1/balancer embryos contain robust H4K20me1 while set-1
homozygous mutant embryos lack detectable H4K20me1 staining
(Figure 5A). Furthermore, by western blot analysis, set-1 mutant
adult extracts lack detectable H4K20me1, as well as H4K20me2
and H4K20me3 (Figure 5B). We conclude that SET-1 is the major
histone methyltransferase required for generation of H4K20me1.
C. elegans SET-4 appears to be the major histone methyltrans-
ferase for converting H4K20me1 to H4K20me2 and H4K20me3.
In set-4(n4600) homozygotes, we observed strongly reduced levels
of H4K20me2 and H4K20me3 and increased levels of
H4K20me1 compared to wild type, both by western blot and
immunofluorescence analyses (Figure 6). In summary, our results
show that SET-1 generates H4K20me1 and SET-4 converts
H4K20me1 to H4K20me2 and H4K20me3, consistent with a
recent report [21]. We note that DPY-27 localization appears
normal in set-1 and set-4 mutants (Figure 5A and Figure 6B),
suggesting that H4K20 methylations are not important for DCC
recruitment.
The X chromosome has lower levels of H4K20me2/3 than
autosomes
In contrast to H4K20me1, the nuclear distributions of
H4K20me2 and H4K20me3 are relatively uniform. To examine
the levels of H4K20me2 and H4K20me3 more closely, we. co-
stained late stage embryos for DPY-27 to mark the X chromo-
some. We observed that H4K20me2 and H4K20me3 were
Figure 3. H4K20me1 ectopically spreads onto the autosomal region of an X;II fusion chromosome. H4K20me1 ChIPs were performed in
wild-type (WT) and YPT41 mixed stage embryos. YPT41 carries a fusion of the right end of X to the left end of chromosome II. The fusion site is
indicated with a dashed line. DPY-27 ChIP-chip and H4K20me1 ChIP-seq enrichment are shown in blue and black, respectively. For each track, the
average of two independent biological replicates is shown as z-scores (standardized log2 ratios of ChIP/Input signals). Genome browser views of
,2 Mb and ,200 kb spanning the fusion site are shown on the top and below, respectively.
doi:10.1371/journal.pgen.1002933.g003
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Figure 4. H4K20me1 enrichment to the X chromosome depends on dosage compensation. Three-fold embryos were stained with DAPI
and antibodies to DPY-27 and H4K20me1. (A) Wild-type (WT) XX hermaphrodite, (B) him-8 XO male, (C) dpy-30(y228) (D) dpy-28(y1), (E) dpy-26(n199),
and (F) dpy-21(e428) hermaphrodites. Left panel shows whole embryos, right panels show enlargements of nuclei. Foci of H4K20me1 X-chromosome
enrichment are absent in males and dosage compensation mutants. Scale bars represent 10 um (left column) and 2 um (enlargements). Monoclonal
antibody 15F11 antibody was used to detect H4K20me1.
doi:10.1371/journal.pgen.1002933.g004
H4K20me1 and Dosage Compensation
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depleted on the X chromosome relative to autosomes (Figure S5).
These differences were not observed in the DCC mutant dpy-21
(Figure S5). We investigated the distribution of H4K20me3 at
higher resolution using ChIP. Similar to other organisms (e.g.
[26]), H4K20me3 is found at higher levels on inactive genes
(bottom 20%) than on active genes (top 20%) (Figure 1C).
However, overall levels are lower on the X chromosome
compared to the autosomes, consistent with immunofluorescence
results (Figure 1C–1E and Figure S5). We conclude that in
hermaphrodites, the X chromosome has higher levels of
H4K20me1 and lower levels of H4K20me2 and H4K20me3
relative to autosomes.
Regulation of the SET-4 H4K20me2/3 methyltransferase
contributes to X-chromosome enrichment of H4K20me1
In principle, these patterns could be generated through
differential activity of SET-1 or SET-4 on X versus autosomes.
For example, SET-1 might be more active in generating
H4K20me1 on the X chromosome compared to autosomes, or
SET-4 could be more active in converting H4K20me1 to
H4K20me2 or H4K20me3 on autosomes compared to the X. To
distinguish between these possibilities, we investigated H4K20me1
patterns in set-4 mutant embryos. We observed that H4K20me1
levels in set-4 mutant embryos were elevated and uniformly
distributed in all nuclear regions, with no detectable X-chromosome
enrichment (Figure 6B, 6C; similar to [21]). Similarly, ChIP
experiments show that H4K20me1 is present at similar levels on the
X chromosome and autosomes in set-4 L3 mutant extracts (Figure
S6). We conclude that the higher level of H4K20me1 on the X
chromosome compared to the autosomes in wild type is achieved at
least in part through higher SET-4 directed conversion of
H4K20me1 to H4K20me2/3 on the autosomes.
If dosage compensation inhibits SET-4 from acting on the X
chromosome, then dosage compensation mutants would be expected
to have increased activity of SET-4 on the X, and as a result, reduced
H4H20me1 and increased H4K20me3 levels compared to wild-
type. To test this hypothesis, we carried out western blot analyses
using dosage compensation mutant dpy-21 and sdc-1 L3 extracts. We
found that the level of H4K20me1 is reduced in these mutants
compared to wild type (Figure 6D and data not shown). Reduced
H4K20me1 is due to inappropriate SET-4 activity, because levels
are greatly increased in dpy-21; set-4(RNAi) or sdc-1; set-4(RNAi)
animals (Figure 6D and data not shown). Furthermore, we found
that the reduction in H4K20me1 in dpy-21 mutants is accompanied
by an increase in the level of H4K20me3, as expected if SET-4 has
increased activity (Figure 6E). These results support the hypothesis
that dosage compensation inhibits SET-4 activity on the X
chromosome, leading to relatively high H4K20me1 levels and
relatively low H4K20me3 levels on X.
The SET-1 H4K20me1 methyltransferase is important for
dosage compensation
We reasoned that if H4K20me1 is important for dosage
compensation, then reducing H4K20me1 levels should impair this
Figure 5. The H4K20me1 methyltransferase SET-1 genetically
interacts with dosage compensation mutants and is required
for repression of X-linked gene expression. (A) Embryos were
stained with DAPI and antibodies to DPY-27 and H4K20me1. In set-1/
hT2G embryos (identified by pharyngeal GFP signal from the hT2G
balancer chromosome), DPY-27 and H4K20me1 are enriched on the X
chromosome. In homozygous set-1mutant embryos, DPY-27 is enriched
on the X, but H4K20me1 is undetectable. Scale bar represents 10 um.
(B) Western blots of H4K20me1, H4K20me2, and H4K20me3 in wild-type
(WT) and set-1(tm1821) mutant adults. The loading control is histone H3.
SET-1 protein is not detected in set-1mutant extract. (C) Tests of genetic
interactions with dosage compensation mutants. Shown is % embry-
onic lethality of wild type (WT), dpy-21(e428) and dpy-28(y1ts) mutants
after RNAi of the indicated gene. RNAi was performed by feeding as
described in Methods. (D) Expression of autosomal genes in blue
(W07G4.4 and act-1) and X-linked genes in red (aco-1, ajm-1, and apl-1)
in the indicated mutants relative to wild-type. Expression levels are
normalized to autosomal gene W07G4.4. Error bars show 95%
confidence intervals.
doi:10.1371/journal.pgen.1002933.g005
H4K20me1 and Dosage Compensation
PLOS Genetics | www.plosgenetics.org 7 September 2012 | Volume 8 | Issue 9 | e1002933
process. To test this hypothesis, we depleted SET-1 in two mutant
backgrounds partially compromised for dosage compensation: null
dpy-21(e428) mutants, which are viable, and a weak temperature-
sensitive allele of dpy-28(y1ts), which shows low embryonic lethality
at the permissive temperature [12,27]. A complete lack of dosage
compensation in XX hermaphrodites results in 100% embryonic
lethality [28]. Therefore, further perturbing the dosage compen-
sation process in the sensitized backgrounds should cause an
increase in embryonic lethality. We first validated the assay by
testing whether knockdown of three different DCC subunits causes
synthetic lethality in the two dosage compensation mutant
backgrounds described above. As expected, RNAi of sdc-2, dpy-
27, or dpy-30 resulted in greatly increased lethality in dpy-21 and
dpy-28(ts) mutant backgrounds compared to wild type (Figure 5C
and data not shown). Using this assay we found that RNAi of set-1
induced synthetic lethality in dpy-21 and dpy-28(ts) mutant
backgrounds, elevating embryonic lethality from 2% in a wild-
type background to 46% and 44% in dpy-21 and dpy-28(ts),
respectively (Figure 5C). RNAi of set-4 or of three other histone
methyltransferases (met-1, met-2, set-2) had no effect (Figure 5C).
The specific synthetic genetic interactions between set-1 and
dosage compensation mutants support the view that H4K20me1 is
important for dosage compensation.
In C. elegans, the DCC represses dosage-compensated genes on
the X by approximately 2-fold. To test directly the role of
H4K20me1 in this repression, we compared the expression of X-
linked dosage-compensated genes to non-compensated autosomal
genes in wild-type and set-1 mutant animals. Because set-1
homozygous mutants are sterile and the X chromosome is not
dosage compensated in the germ line, we focused on genes
expressed in the soma. In order to control for possible germline
effects, we performed analyses in glp-1 mutant animals, which lack
a germ line. Finally, as some X-linked genes are not dosage
compensated, we chose X-linked genes that are upregulated in
dosage compensation mutants dpy-21 or dpy-28. As expected, we
found that the expression of three X-linked genes (aco-1, ajm-1, and
apl-1) relative to two autosomal genes (W07G4.4 and act-1) is
unchanged in glp-1 mutants and significantly increased in dpy-21
and/or dpy-28 mutants (Figure 5D). Similar to the DCC mutants,
we observed a significant increase in the expression of dosage
compensated X-linked genes relative to autosomal genes in the set-
1 mutant (Figure 5D). These results show that H4K20 mono-
methylation mediated by SET-1 has a role in repression of dosage-
compensated X-linked genes.
Discussion
Downregulation of X-linked gene expression during C. elegans
dosage compensation allows study of gene expression mechanisms
that act over large chromosomal regions. Previous studies have
identified a condensin-like complex and other chromatin-associ-
ated proteins required for this process, but the mechanism by
which these proteins lower X-linked gene transcription is not
known. Here we show that the DCC generates X-linked
enrichment of the post-transcriptional histone modification
H4K20me1 and that this modification is important for dosage
compensation.
As we observed here for C. elegans, H4K20me1 in other
organisms is enriched on gene regions and its level is positively
correlated with gene expression [29]. Although H4K20me1 levels
are highest on actively transcribed genes, functional experiments
in vertebrates and Drosophila point to a repressive role in gene
Figure 6. The SET-4 histone methyltransferase is necessary to generate H4K20me2 and H4K20me3. (A) Wild-type (WT) and set-4(n4600)
mutant embryos were stained for DNA (DAPI), and H4K20me1, H4K20me2, or H4K20me3. H420me1 levels are higher and H4K20me2 and H4K20me3
levels strongly reduced in set-4 mutant embryos. Scale bar, 10 um. (B) Enlargements of nuclei in wild-type and set-4(n4600) mutant embryos stained
for DNA (DAPI), H4K20me1, and DPY-27. In set-4 embryos, H4K20me1 does not show enrichment in DPY-27 positive regions. Confocal settings for
H4K20me1 in set-4 were reduced to allow comparison with wild-type images. Scale bar, 2 um. (C) Western blots of extracts made from wild-type and
set-4 adults, probed for H4K20me1, H420me2, or H4K20me3. Histone H3 is a loading control. Compared to wild type, set-4 mutants have increased
H4K20me1 levels, and reduced H4K20me2 and H4K20me3 levels. (D, E) Western blots of H4K20me1 (D) and H4K20me3 (E) in wild-type and dpy-21 L3
mutant extracts. Lower panels show H3 loading controls. (D) H4K20me1 abundance is lower in dpy-21 than in wild type. (E) H4K20me3 abundance is
higher in dpy-21 mutant L3 extract than in wild type. In (D) RNAi of set-4 was additionally performed. H4K20me1 abundance is elevated in both wild-
type and dpy-21 after depletion of set-4. The following primary antibodies were used: H4K20me1 (Diagenode SN-147), H420me2 (Kimura 2E2),
H4K20me3 (Abcam ab78517).
doi:10.1371/journal.pgen.1002933.g006
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expression. Knockdown of the H4K20me1 methyltransferase
Pr-Set7 in human cells caused a two-fold upregulation of genes
normally harbouring H4K20me1 [29], and mutation of Pr-Set7 in
Drosophila leads to position effect variegation, a hallmark of genes
required for heterochromatic gene repression [30]. H4K20me1 is
also associated with the inactive X chromosome during X
inactivation in vertebrates [31]. Therefore, the high levels of
H4K20me1 we observed on the C. elegans X chromosome are
consistent with a role in dosage compensation-mediated repression
of gene expression.
What is the mechanism that leads to higher H4K20me1 levels
and lower H4K20me3 levels on the hermaphrodite X chromo-
somes relative to autosomes? Our results suggest that this is
achieved at least in part through DCC inhibition of SET-4
activity on X. Lower conversion of H4K20me1 to H4K20me2/3
by SET-4 on the X chromosome would lead to relatively higher
H4K20me1 levels and lower H4K20me2/3 levels there. Several
observations support this model. First, dosage compensation
mutants show lower overall H4K20me1 levels and higher
H4K20me3 levels compared to wild type. Second, the lower
overall H4K20me1 level in DCC mutants is due to inappropriate
SET-4 activity, supporting the idea that active dosage compen-
sation inhibits SET-4 activity. Third, the difference in
H4K20me1 levels on the X versus the autosomes is abolished
in set-4 mutants, indicating a role for SET-4 in generating the
asymmetry. We propose that a component of the DCC prevents
SET-4 from acting on the X chromosome, leading to mainte-
nance of H4K20me1 on X, whereas H4K20me1 is preferentially
converted to H4K20me2/3 on the autosomes. Because
H4K20me1 levels are similar on X and autosomes in set-4
mutants, SET-1 might be equally active in generating
H4K20me1 on all chromosomes.
Our results suggest that of the three H4K20 methylation states,
H4K20me1 is the key modification for dosage compensation.
Whereas loss of dosage compensation leads to lethality of XX
embryos, set-4 null mutants, which have strongly reduced levels of
H4K20me2 and H4K20me3, are viable, and RNAi of set-4 does
not enhance lethality of DCC mutants. This suggests that these
modifications are not necessary for dosage compensation. In
contrast, RNAi depletion of maternal and zygotic set-1 leads to loss
of H4K20me1 and embryonic lethality, set-1 genetically interacts
with dosage compensation mutants, and set-1 mutants show
upregulation of X-linked gene expression.
When does H4K20me1 function in dosage compensation? The
DCC is recruited to the X chromosome around the 30-cell stage
whereas X-chromosome enrichment of H4K20me1 occurs several
hours later. This difference in timing suggests that there might be
two separable aspects of dosage compensation during embryo-
genesis, for example initiation and maintenance. Although the
DCC is recruited to the X in early embryogenesis, it is not yet
known when repression of X-linked gene expression is initiated.
The DCC might be active immediately after recruitment or might
become active later in embryogenesis. Furthermore, although
H4K20me1 becomes highly enriched on X in late embryogenesis,
it is possible that a basal level on the X chromosome is functional
earlier. Because the DCC component DPY-27 shows apparently
normal localization to the X chromosome in the absence of SET-1
or SET-4, H4K20me1 does not appear to be a recruitment signal
for the DCC. Instead, H4K20me1 may be important for the
function of the DCC in downregulating gene expression. Key
future questions to address are when during embryogenesis X-
linked gene expression is initially downregulated, and when
H4K20me1 function is necessary.
Regulation of histone modification levels also occurs during
dosage compensation in other organisms. For example, in
Drosophila, where gene expression on the single X chromosome
in males is upregulated two-fold to match that of the two X
chromosomes in females, dosage compensation acts to increase
H4K16ac levels on the single male X. In addition, the inactive X
chromosome of female mammals displays high levels of several
histone modifications, including H4K20me1 [31]. H4K20me1
enrichment correlates with Xist expression, is independent of
transcriptional silencing, and marks the early steps of X
inactivation [31].
In addition to the strong enrichment of H4K20me1 on the X
chromosome in C. elegans, Liu et al. showed that several marks of
gene activity, including H4K16ac, were lower on X linked genes
than on autosomal genes [15]. Using immunofluorescence assays
on gut nuclei, a recent report by Wells et al. showed that the X/A
difference in H4K16ac levels depends on dosage compensation
and on sir-2.1, a putative H4K16 deacetylase [21]. It is not clear if
H4K16Ac plays a role in dosage compensation as depletion of sir-
2.1 did not genetically interact with a DC mutant. The enzyme
that generates H4K16Ac is not yet known.
Using immunofluorescence assays, Wells et al. also observed that
H4K20me1 enrichment on X is dependent on dosage compensa-
tion, and on SET-1 and SET-4 [21]. Our immunofluorescence
results are broadly similar, and our ChIP experiments give a higher
resolution view, strengthening these conclusions. In support of a role
for methylation of H4K20 in dosage compensation, Wells et al.
observed that simultaneous reduction of set-1 and set-4 by RNAi
could rescue mutant males that normally die due to active dosage
compensation. However, the H4K20 methylation state was not
determined after simultaneous depletion of set-1 and set-4, so the
specific alteration of methylation of H4K20 that caused rescue is not
known. The reported X/A differences in H4K16ac levels also
depended on set-1 and set-4, suggesting that H4K16Ac might be
regulated by H4K20 methylation state. Although the exact
mechanisms of dosage compensation vary, studies in different
organisms suggest that global regulation of H4K16ac and
H4K20me1 levels might be a conserved feature of these chromo-
some-wide gene regulation mechanisms.
Our results indicate that H4K20me1 is important for
repression of X-linked gene expression. How might H4K20me1
function in transcriptional repression? Several links in the
literature suggest roles for H4K20me1 in chromatin compaction.
For example, the Malignant-Brain-Tumor (MBT) domains of
human L3MBTL1 compact nucleosomal arrays by recognizing
mono and dimethylation of H4K20 and H1bK26 [32]. Further-
more, L3MBTL1 has transcription repressor activity that is
enhanced by Pr-Set7, and its chromatin association depends on
H4K20me1 [33,34]. It is not yet known whether C. elegans MBT
repeat proteins LIN-61 or MBTR-1 are involved in dosage
compensation or bind H4K20me1.
H4K20me1 has also been shown to be important during
mitosis. H4K20me1 levels are high on mitotic chromatin ([35,36]
and this study), and in mammalian cells inhibition of Pr-Set7
leads to defects in cell cycle progression [36,37,38,39]. Although
the function of H420me1 in cell cycle progression is not yet
understood, a key aspect of the loss of function phenotype is
reduced chromosome compaction. Furthermore, a recent study
demonstrated that two components of condensin II, N-CAPD3
and N-CAPG2, can directly bind H4K20me1 [35]. This raises
the exciting possibility that condensin IDC might function to
compact chromatin through binding H4K20me1. Increased
compaction of the X chromosome relative to the autosomes
might reduce access by RNA polymerase, leading to lower
H4K20me1 and Dosage Compensation
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X-linked gene expression. Consistent with this idea, DCC
mutants were recently shown to have increased RNA polymerase
II levels on the X [13]. We propose that condensin complexes
and H4K20me1 might be intimately linked in diverse chromatin-
regulating events.
Methods
Worm culture and strains
The following strains were used and cultured using standard
methods (Brenner, 1974): TY0621 [yDp1(IV,V:f); dpy-26(n199) unc-
30(e191) IV], DR1410 [dpy-27(y56)/qC1 III], TY1621 [unc-
49(e382) dpy-28(y1ts) III], TY148 [dpy-28(y1ts) III], CB428 [dpy-
21(e428) V], KK0423 [dpy-21(e428) par-4(it57ts) V], TY1936 [dpy-
30(y228) V/nT1[unc-?(n754) let-?](IV;V)], SS1075 [set-1(tm1821)/
hT2G(qIs48) I;III], JA1574 [set-1(tm1821)/hT2G(qIs48) I;III],
MT14911 [set-4(n4600], YPT41 [X;II].
Chromatin immunoprecipitation analyses
Late embryo (LE) extracts were prepared by growing wild-type
N2 adult worms from synchronized L1s in standard S-basal
medium with shaking. Worms were fed HB101 E. coli and grown
at 20uC until they were gravid, approximately 70 hours. Embryos
were obtained by dissolving adult worms with bleach, and then
the embryos were aged by incubating in M9 media for 3.5 hrs at
20uC with gentle rocking. The embryos were washed once with
PBS and flash frozen in liquid nitrogen, then processed for ChIP
as in [40]. Wild-type, dpy-21(e428), and set-4(n4600) L3 and fem-2
YA animals were grown and ChIPs performed as in [41] except
that DNA was sonicated to a size range of 200–400 bp. EE and
L3 in Figure 1 are from [15] (Abcam ab9051; lot 104513).
H4K20me1 ChIP conditions were: LE (1 mg extract and 5 ul
Diagenode SN-147), fem-2 young adults (1.25 mg extract and
3 ug Abcam ab9051 lot 104513), dpy-21 L3s (500 ug extract and
2 ug Abcam ab9051 lot 104513), WT and set-4 L3s in Figure S6
(500 ug extract and 2 ug Abcam ab9051 lot 602259), WT L3 in
Figure S7 (500 ug extract and 5 ul Diagenode SN-147). The
Diagenode SN-147 and Abcam ab9051 antibodies give concor-
dant patterns by ChIP in L3 extracts (Figure S7A, S7B).
H4K20me3 ChIP conditions: 500 ug L3 extract and XX Abcam
78517 lot 827718. Antibodies used for ChIP, western blot, or
immunofluorescence were tested for specificity to histone peptide
tails using dot blots ([42] and http://compbio.med.harvard.edu/
antibodies/).
Early Embryo, Late Embryo, L3, and dpy-21 L3 H4K20me1
ChIPs and L3 H4K20me3 ChIPs were hybridized to a C. elegans
full-genome tiled microarray (NimbleGen 2.1, Roche). For
H4K20me1 ChIPs, log2 ratios of IP/Input were obtained and
standardized so the autosomal signal had mean 0 and standard
deviation 1. The H4K20me3 L3 ChIP dataset was processed
similarly except that all chromosome regions were used. fem-2
young adult (Figure 1) and WT and set-4 L3 H4k20me1 ChIPs
in Figure S6 were sequenced on the Illumina platform, aligned
using BWA with default settings [43], normalized using BEADS
[44], then converted to log2 ratios of BEADS scores (enrich-
ment relative to input) and standardized so the mean of the
autosomal signal was 0 and the standard deviation 1. Biological
ChIP-chip and ChIP-seq replicates were averaged after
standardization. Gene profile plots (Figure 1 and Figure S6)
were generated by aligning genes at their TSS and TES
(WS190/ce6). The genomic regions 1 kb upstream to 1 kb
downstream from TSS and 1.5 kb upstream to 1 kb down-
stream from TES were divided into 50-bp bins. Genes were
grouped into top 20% and bottom 20% expressed and
autosomal and X-linked genes. Mean signals for each group
of genes and each bin were plotted as well as the 95%
confidence intervals of the mean (as error bars). Profile plots of
intergenic regions were obtained by first identifying regions of
at least 10 kb length without any annotation (WS190/ce6) (491
such regions on autosomes, 193 on chromosome X). The
regions were aligned at their center and the genomic regions
from 5 kb upstream to 5 kb downstream from the center were
divided into 50 bp bins. Mean signals for the autosomal and X
intergenic regions were plotted as well as the 95% confidence
intervals of the means.
Boxplots (Figure 1 and Figure S7) were obtained after 1 kb
median smoothing along the chromosomes of the respective
standardized log2 ratios. Each box indicates the median with the
center line and extends from the 25th to the 75th percentile of the
standardized log2 ratios; whiskers extending from the box indicate
the 2.5th and 97.5th percentiles.
Transcript data for the EE, LE, L3 and YA stages were
obtained from the modENCODE DCC (http://intermine.
modencode.org). The platform was a single color 4-plex Nimble-
gen expression array with 72,000 probes (three 60-mer oligo
probes per gene). Quantile normalization [45] and the Robust
Multichip Average (RMA) algorithm [46] were used to normalize
and summarize the multiple probe values per gene to obtain one
expression value per gene and sample.
Western blotting
Sample buffer was added directly to worms, samples heated to
65uC for 10 minutes, sonicated for 15 minutes (30 sec in/30 sec
out), incubated at 65uC for 5 min and finally boiled at 95uC for
5 min. Proteins were separated on 4–12% NuPage SDS pre-cast
gels (Invitrogen). The following antibodies were used: anti-
H4K20me1 (Abcam ab9051 at 1:2000), anti-H4K20me2 (H.
Kimura monoclonal antibody 2E2 at 1:20,000), anti-H4K20me3
(Abcam ab78517 at 1:500), anti-H3 (Active Motif 39163 at
1:8000), and anti-SET-1 (SDI SDQ3895). JA1574 was used to
obtain set-1 homozygotes in Figure 5B.
Immunostaining
Immunostaining of embryos and dissected intestines was done
using methanol/acetone fixation as in [47] (Figure 2; Figure 5;
Figures S1, S2, and S4) or using methanol fixation as in [48]
(Figure 4, Figure 6, Figure S5). Germline immunofluorescence
experiments (Figure S3) were carried out after dissecting worms in
egg buffer containing 0.1% Tween 20 and fixation in 1%
formaldehyde in egg buffer [49]. SS1075 was used for the IF
experiment in Figure 5A. Primary antibodies used are indicated in
the figure legends. Antibody concentrations used were: anti-
H4K20me1 Kimura 1F11 (1:40,000), anti-H4K20me1 Diagenode
SN-147 (1:100,000), anti-H4K20me1 Abcam ab9051 (1:400 for
Figure S1; 1:5000 for Figure S3), anti-H4K20me2 Kimura 2E2
(1:25,000), anti-H4K20me3 ab78517 (1:200), anti-DPY-27 SDI
SDQ3995 (1:4000), anti-GFP Abcam ab290 (1:6000), anti-
H3S10p Kimura 10H12 (1:1000), anti-HIM-8 (1:250). Secondary
antibodies were purchased from Jackson ImmunoResearch or
Molecular Probes.
qPCR quantification of gene expression
Total RNA was extracted from N2 (wild type), dpy-21(e428),
dpy-28(y1), or set-1(tm1821) L3 worms grown at 25uC using
TriPure (Roche). RNA was further purified using an RNeasy
column (Qiagen). Reverse transcription was carried out using
the Invitrogen SuperScript III First-Strand Synthesis System.
H4K20me1 and Dosage Compensation
PLOS Genetics | www.plosgenetics.org 10 September 2012 | Volume 8 | Issue 9 | e1002933
Quantitative PCR was performed using primers specific to the
target genes:
Chromosome V:
W07G4.4 F: GCAATCGCTCCAGCCGTTAACAAT; R:
TCGTCCAGATGGAACGACAGATGA
act-1 F: TGCAGAAGGAAATCACCGCTCTTG; R: AAG-
CACTTGCGGTGAACGATGGAT
Chromosome X:
apl-1 F: ACGACGACGATGAGGATGATGCTT; R: TGA-
ACTTCTCGGCTCCCTTTGGAT
aco-1 F: CAAGATCAACCCAGTATGCCCAGT; R: AC-
CTGATGGACGATTCCAGATCCT
ajm-1 F: TCGTCTTGATGAGATGGAACGCGA; R: AAG-
TTCTGCGTTACGTTGGGCTTG
Gene expression levels in each strain were normalized to the
levels of the autosomal gene W07G4.4. Expression of each gene in
wild-type N2 was then set to 1 and mutant expression levels
expressed relative to N2.
Genetic interaction tests
RNAi by feeding was performed on N2 (wild type), dpy-21(e428)
and dpy-28(y1) animals as follows: 3–5 L3 larvae were placed on
RNAi bacteria for three days at 15uC, transferred to new RNAi
plates for 24 hours, transferred again after 24 hours, then
removed. The progeny on the latter two plates were scored for
embryonic lethality. We note that RNAi of set-1 leads to
embryonic lethality in the N2 (wild-type) background in embryos
produced in the next 24 hours of RNAi feeding, or if RNAi is
performed by injection (not shown). RNAi plates were prepared as
in [50]. The following RNAi clones were used from [51,52]: sdc-2
(C35C5.1), set-1 (T26A5.7), set-2 (C26E6.9), met-1 (C43E11.3), and
met-2 (R05D3.11). The set-4 RNAi clone was made by PCR
amplifying and cloning a portion of the set-4 gene into RNAi
feeding vector L4440. The primers used were: atacgaattca-
caggtcggc and tgctactacgcttgtcgtcg. RNAi plasmids were in the
HT115(DE3) bacterial strain, which was used as the control. All
RNAi clones were verified by sequencing.
Assaying ectopic spreading
H4K20me1 ChIPs were performed in mixed stage embryos
from wild-type N2 normal karyotype strain (2 replicates) and in
YPT41 X;II fusion strain (2 replicates) using methods described
previously [53]. 1 mg of total embryo extract and 2 ug of
H4K20me1 antibody (Abcam ab9051) were used per ChIP. The
ChIP DNA was prepared for Illumina multiplex sequencing with
slight modifications to the manufacturers protocol [54]. Briefly,
sequencing libraries were prepared from half of the ChIP DNA
and 10 ng of corresponding input DNA. NEB Klenow, T4 DNA
polymerase and T4 PNK were used to repair ends at 20uC for
30 min. Exo(-) Klenow fragment and dATP was used to add
adenosine at the 39 ends for 1 hour at 37uC. DNA was ligated to
multiplex adaptors (Illumina) and amplified by PCR, introducing
the following indices: N2 H4K20me1 ChIP index #6
(GCCAAT), N2 Input index #12 (CTTGTA), YTP41
H4K20me1 ChIP replicate 1 index #2 (CGATGT), input index
#3 (TTAGGC), and H4K20me1 ChIP replicate 2 index #1
(ATCACG), input index #5 (ACAGTG). DNA between 200–
500 bp in size was gel purified. Multiplexed single-end sequenc-
ing was performed by GAIIx at the UNC high-throughput
sequencing facility. The sequencing reads, obtained from the
Illumina pipeline in fastq format, were aligned to the ce6
(WS190) version of the C. elegans genome with Bowtie [55], using
default parameters. Each sequence read was extended to
calculate coverage per base pair using MACS [56]. The coverage
from the input data was subtracted from that of the ChIP data,
and ChIP enrichment was standardized by z score transforma-
tion.
Datasets
Accession numbers for datasets generated in this paper are listed
in Table S1.
Supporting Information
Figure S1 Nuclear abundance of H4K20me1 is cell cycle
regulated. Wild-type embryos were stained with DAPI (blue) and
antibodies to H3S10ph (red) and H4K20me1 (green). In early
embryos, H4K20me1 levels are higher on condensed prometa-
phase and metaphase chromosomes, marked with the mitotic
marker H3S10ph, than in interphase nuclei. Scale bar represents
10 um. Monoclonal antibody 10H12 was used to detect
H4K20me1.
(PDF)
Figure S2 H4K20me1 enrichment on the X chromosome in
adult somatic cells depends on dosage compensation and SET-1.
Dissected adult tissues were stained as in Figure 2. In wild-type
(WT) XX intestinal nuclei (A) DPY-27 and H4K20me1 co-localize
on the X chromosomes. H4K20me1 is diffusely nuclear in
intestinal cells of wild-type XO males (B) and XX animals
defective in dosage compensation: (C) dpy-21(e428), (D) dpy-
26(n199), and (E) dpy-28(y1). Intestinal nuclei of set-1 mutant
animals (F) lack detectable H4K20me1. The brightness of
H4K20me1 in panel F is over-exposed to show the lack of
nuclear stain. Scale bar represents 10 um. Monoclonal antibody
15F11 was used to detect H4K20me1.
(PDF)
Figure S3 H4K20me1 exhibits dynamic localization in the germ
line. (A) Dissected gonads from wild-type hermaphrodites were
stained with DAPI and an antibody to H4K20me1. H4K20me1
levels are high in the distal region corresponding to premeiotic
nuclei. Levels drop as nuclei move proximally and enter meiosis.
(B) Gonads were stained with DAPI (red) and antibodies to
H4K20me1 (green) and an X-chromosome binding protein HIM-
8 (blue). H4K20me1 is present on the X in transition zone nuclei
in early meiotic prophase. In mid-pachytene, H4K20me1 is
significantly depleted from the X. In late pachytene nuclei,
H4K20me1 relocalizes to the X. The Abcam ab9051 antibody
was used to detect H4K20me1.
(PDF)
Figure S4 H4K20me1 enrichment on the X chromosome
depends on dosage compensation. This figure resembles Figure 4,
but shows results with a different antibody to H4K20me1. Three-
fold embryos were stained with DAPI and antibodies to DPY-27
and H4K20me1. In wild-type XX embryos (A) DPY-27 and
H4K20me1 are concentrated on the X chromosome. In XO
embryos (B) DPY-27 is absent and H4K20me1 is diffusely nuclear.
In XX embryos deficient in dosage compensation, dpy-21(e428)
(C), dpy-26(n199) (D), and dpy-28(y1) (E), H4K20me1 is diffusely
nuclear. Scale bars represent 10 um (A–E, left column) and 2 um
(A–E, enlargements). The Diagenode SN-147 antibody was used
to detect H4K20me1.
(PDF)
Figure S5 H4K20me2 and H4K20me3 show reduced staining
on X chromosomes compared to autosomes. Wild-type (WT) and
dpy-21 mutant embryos stained for DNA (DAPI), DPY-27, and (A)
H4K20me2 or (B) H4K20me3. The X chromosome, marked by
H4K20me1 and Dosage Compensation
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DPY-27, shows lower staining of both modifications than other
regions. In dpy-21 mutants, this difference is not observed.
(PDF)
Figure S6 Enrichment of H4K20me1 on X is abolished in set-4
mutants. (A) Genome browser tracks of H4K20me1 ChIP-seq
signals across representative regions of chromosome I and
chromosome X in wild-type (WT) and set-4 mutant L3 larvae.
Signal is displayed as z-scores (standardized log2 ratios of ChIP/
Input signals). Enrichment of H4K20me1 on X is lost in set-4
mutants. (B) Plots of H4K20me1 signal across the TSS (transcript
start site) and TES (transcript end site) of genes on X (red) and
autosomes (blue). Genes in the top 20% of expression (dark shades)
and bottom 20% (light shades) are plotted separately. (C) Plots of
H4K20me1 signal centered at intergenic regions at least 5kb from
any annotated feature. (D) Box plots of overall H4K20me1 signals
on each chromosome. Each box shows the median and extends
from the 25th to the 75th percentile of the z-scores in the set;
whiskers extending from the box indicate the 2.5th and 97.5th
percentiles.
(PDF)
Figure S7 Consistency of different H4K20me1 antibodies in
ChIP. (A) Correlation between ChIP-chip signals using antibodies
to H4K20me1 from Abcam and Diagenode (r = 0.95). (B) Plots of
H4K20me1 signal across the TSS (transcript start site) and TES
(transcript end site) of genes on X (red) and autosomes (blue).
Genes in the top 20% of expression (dark shades) and bottom 20%
(light shades) are plotted separately. Plots generated using data
from the two antibodies show similar patterns.
(PDF)
Table S1 ChIP dataset accession numbers. modENCODE or
GEO accession numbers for datasets generated or used in the
paper. modENCODE data can be obtained from http://data.
modencode.org/ or modMine: http://intermine.modencode.org/;
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